Phase 2 N=141 Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids
Uterine Fibroids · Adhesions
Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants
N/A N=93 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
Asherman's Syndrome
Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009
N/A N=23 PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film
Intrauterine Adhesion
Primary: Safety (Adverse Events) — 0 device related adverse event
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
N/A N=161 Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.
Asherman Syndrome
Primary: The Zung Self-Rating Anxiety Scale Scores Before and After the Intervention — 36.4; 37.3; 32.1; 38.5 units on a scale(raw scores) — p=<0.001
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas
N/A N=3 Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata
Uterine Fibroids · Leiomyoma · Menorrhagia
Primary: Number of Adverse Events — 1 Participants
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
N/A N=990 Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
Contraception
Primary: Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal Sterilization — 39; 28…
N/A N=282 Single or Double-layer Uterine Closure Techniques
Uterine Scar · Cesarean Section Complications · Cesarean Section; Dehiscence
Primary: Number of Participants With Niche Visualized by Saline Infusion Sonography — 40; 53; 25; 23 Participants — p=0.05
N/A N=171 Adjuvant Therapy for Intrauterine Adhesions Between Two Groups
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 6.5; 8 Units on a scale — p=<0.05
N/A N=15 Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy
Fibroid · Myoma · Leiomyoma
Primary: Number of Sites Adherent to the Uterus — 1.1; 0.6 Adhesion Sites
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
N/A N=60 Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum
Placenta Accreta
Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants
N/A N=11 Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator
Abnormal Uterine Bleeding · Infertility
Primary: Percentage of Tissue Removed — 97.5 Percentage of tissue removed
Phase 2 N=40 Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas
Endometriosis
Primary: Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation — -56.86; -77.72; -36.69; -66.84 percentage of serum AMH change
N/A N=74 HOME Study: Hysteroscopic Office Myomectomy Evaluation
Uterine Fibroids · Polyps
Primary: Percent Reduction in Target Pathology Volume — 96.9; 99.9 percentage of fibriods/polyps
N/A N=100 SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF
Infertility
Primary: Patient Satisfaction — 4.92; 4.84 units on a scale — p=0.57
N/A N=44 Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine
Endometritis
Primary: Endometritis Incidence — 0; 0 participants
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
N/A N=21 A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12-months — 20 participants
N/A N=31 ESS505 Pre-hysterectomy Protocol
Contraception
Primary: Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation — 36; NA; NA; NA Occluded fallopian tubes
Phase 3 N=105 Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Early Phase 1 N=27 Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants With Adverse Events — 0; 0 Participants
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
N/A N=24 Development of an Intrauterine Pressure Threshold to Confirm Tubal Occlusion
Sterilization, Female · Fallopian Tube Occlusion
Primary: Intrauterine Fluid Volume Lost — 2.2; 7.8 ml
Phase 4 N=753 Seprafilm® Adhesion Barrier and Cesarean Delivery
Adhesions · Cesarean Section · Delivery, Obstetric
Primary: Incidence of Adhesions — 75.6; 75.9 percentage of patients with adhesions